Leming Shi, Ph.D.

Leming Shi, Ph.D.

Dr. Leming Shi is a professor at the School of Pharmacy and the School of Life Sciences of Fudan University in Shanghai, China where he established the Center for Pharmacogenomics. Dr. Shi’s research focuses on pharmacogenomics, bioinformatics, and cheminformatics aiming to realize personalized medicine by developing biomarkers for early cancer diagnosis and targeted therapy. As a Principal Investigator at the US Food and Drug Administration (FDA) from 2003 to 2012, Dr.

Kenneth D. Noonan, Ph.D.

Kenneth D. Noonan, Ph.D.

Ken’s life-long professional focus has been on all aspects of the global life sciences industries.  Currently Ken is the Managing Director of T/K Associates LLC, a specialist consulting firm dedicated to supporting start-ups in the life sciences space with commercial, financial and business planning. He is also a Venture Partner at Advanced Technology Ventures (ATV) a well- established U.S. venture fund.  From 2001 – 2013 Ken was the Senior Partner heading the European Life Sciences Practice at L.E.K. Consulting LLP; a global management consultancy.

Steve McPhail

Steve McPhail

Steve has significant senior management, scientific and operational experience in variety life science- focused businesses. He was President and Chief Executive Officer of Expression Analysis, Inc. (EA), a genomic services company, providing genomic technology solutions to a variety of market segments to advance clinical research with the goal of improving the diagnosis, treatment and management of complex disease.

Richard A. Leach, Ph.D.

Richard A. Leach, Ph.D.

Richard A. Leach, Ph.D. is Vice President of Business Development at Complete Genomics. Collaborating with thought leaders across the globe, his primary focus is to bring genome sequencing to broad clinical practice. Prior to Complete Genomics, he was the Vice President of Scientific Services for deCODE Genetics in Reykjavik, Iceland, while it was the world’s largest and most productive genetics research company. Joining with Shady Grove Center for Preimplantation Genetics and Integramed, he co-created advanced human embryo diagnostics for pre-implantation genetic diagnostic applications.

Katherine Call, Ph.D.

Katherine Call, Ph.D.

Katherine M. Call has extensive experience in the fields of biologics and genomics, having identified and validated disease genes and drug targets and advanced molecules into development in several therapeutic areas. She is currently Senior Director and Head, Proteogenomics, a newly established group with a strong translational science component in the Sanofi-Genzyme R&D Center.  Dr. Call was Head of US Biologics Research from 2010 - mid 2012 and led the establishment of Sanofi Discovery Biotherapeutics globally from 2005 - 2007.

Michael (Ted) Burczynski, Ph.D.

Michael (Ted) Burczynski, Ph.D.

Michael (Ransom) Burczynski received his Ph.D. in Pharmacology and Toxicology from the University of Pennsylvania, and was awarded with an AACR young investigator award during his thesis research. He conducted seminal research in the nascent field of toxicogenomics during his postdoctoral fellowship at Johnson and Johnson.

Carrie Browning, MS

Carrie Browning, MS

Carrie Browning, Senior Pharma Business Manager with Illumina residing in Raleigh, North Carolina works with Pharmaceutical and CRO clients to assist with development of genomic biomarker applications. Carrie was most recently at BioStorage Technologies, where she was the Program Director for the Targeted Medicine program integrating specimen management and biorepository services with genomic biomarker analysis for drug development.

Rebecca Blanchard, Ph.D.

Rebecca Blanchard, Ph.D.

Rebecca Blanchard is the head of Clinical Pharmacogenomics within the Human Genetics and Pharmacogenomics department at Merck & Co., Inc.  Dr. Blanchard’s career in academia and at Merck has spanned preclinical, translational, and clinical development across multiple therapeutic areas.  Rebecca’s education includes a B.S. in Pharmacy from Albany College of Pharmacy and a Ph.D. in Pharmaceutical Chemistry from the University of Utah in Salt Lake City, Utah.

J. Carl Barrett, Ph.D.

J. Carl Barrett, Ph.D.

Dr. Carl Barrett is Vice President of Translational Science in the Oncology Innovative Medicines Unit at AstraZeneca Pharmaceuticals. His responsibility is to develop and execute biomarker strategy and translational sciences efforts to support compound development from research through early and full development in oncology. Previously, he was Global Head of Oncology Biomarkers and Imaging in Novartis Oncology Translational Medicine.  Prior to joining Novartis, Dr. Barrett was the founding Director of the NCI Center for Cancer Research. Prior to joining NCI, Dr.

Pages

Subscribe to National Biomarker Development Alliance (NBDA) RSS